News / Taiwan / economic_daily
LongLife Biotech Reports 21% Revenue Growth in August, Advances CAR001 Trials
Health Technology · Biotechnology · economic_daily · 2026-09-01
6712
LongLife Biotech announced August revenue of NT$109 million, a 21% year-over-year increase, driven by growth in cell therapy and CDMO services.
What Happened
Steady Revenue Growth: LongLife Biotech reported August revenue of NT$109 million, marking a 21% year-over-year and 11% month-over-month increase. Cumulative revenue for the first eight months reached NT$669 million, up 17% compared to the previous year, supported by steady progress in cell storage, manufacturing services, and CDMO operations.
mRNA Technology Trends: The company highlighted the growing global interest in mRNA-based cancer immunotherapy. Recent clinical successes by Moderna and Merck have validated the clinical and commercial potential of this technology for treating refractory cancers, reinforcing the strategic direction of LongLife’s own research.
Clinical Pipeline Progress: LongLife’s core product, CAR001, utilizes AI-assisted design and mRNA non-viral electroporation technology. The therapy has successfully completed Phase I trials and is currently in the Phase IIa stage, focusing on patients with advanced or recurrent refractory solid tumors.
Competitive Edge: By focusing on innovative cell therapy solutions, LongLife aims to provide patients with alternatives to traditional treatments. As clinical trials progress, the company expects to strengthen its position in the solid tumor treatment market.